# An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

> **NCT05667493** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 1400 (estimated)

## Conditions studied

- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

## Interventions

- **DRUG:** Eplontersen

## Key facts

- **NCT ID:** NCT05667493
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-11-30
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667493, "An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05667493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*